Novo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security Breach

NVO stock gains 3% as the United Kingdom becomes Europe's first country to approve the daily GLP-1 Wegovy weight-loss pill, overshadowing an IT security breach.

Zacks Investment Research • 10 hours ago

Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About

Pfizer aims to enter the weight loss drug market, and one platform should be the workhorse of this effort. That workhorse, called berobenatide, is performing as well as the company's been hoping.

The Motley Fool • 8 hours ago

Wegovy GLP-1 pill could reshape Britain's £220bn food market, warns brokers

The approval of a tablet version of the GLP-1 drug Wegovy in the UK could mark a turning point for Britain's food industry, according to Shore Capital, as weight-loss drugs move from a healthcare trend to a force capable of changing consumer spending habits. Retail analyst Clive Black said the Medicines & Healthcare products Regulatory Agency's decision to approve an oral version of the Novo Nordisk (NYSE:NVO) obesity treatment was "a notable moment for the UK food system" because pills are likely to be more accessible than injections.

Proactive Investors • 13 hours ago

Novo Nordisk hit by cyber incident, probes data breach

Novo Nordisk said on ​Thursday it has identified a ‌security incident involving unauthorized access to a limited number of internal ​IT systems.

Reuters • Jun 11, 2026

Novo Nordisk's Wegovy Weight Loss Pill Approved in the U.K.

The U.K. regulator is the third regulatory authority to license the medicine as the Danish drugmaker seeks to regain its lead in the obesity market.

WSJ • Jun 11, 2026

UK health regulator approves Novo Nordisk's weight-loss pill

Britain's medicines regulator approved Novo Nordisk's weight-loss pill on Thursday, giving patients ​a new needle-free obesity treatment option and bolstering the ‌Danish drugmaker's first-to-market lead against U.S. rival Eli Lilly.

Reuters • Jun 11, 2026

Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet

On Thursday, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk A/S' (NYSE:NVO) Wegovy pill, clearing the company's first daily oral weight-management treatment for adults with obesity or overweight conditions linked to weight-related health issues.

Benzinga • Jun 11, 2026

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults living with obesity and overweight versus placebo in addition to diet and exercise Semaglutide tablets will be available as a once-daily treatment, an alternative to weekly injections for adults living with obesity or overweight with a weight-related condition, alongside diet and exercise After this approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), Novo Nordisk anticipates Wegovy® pill will be available via private prescription within weeks Bagsværd, Denmark, 11 June 2026 – Wegovy® pill, the new daily weight management tablet, has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity, offering a first-of-its-kind alternative to injectable treatments for adults. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy® pill (semaglutide tablets), an oral glucagon-like peptide-1 (GLP-1) receptor agonist licensed for weight management in adults living with obesity (initial Body Mass Index (BMI) ≥30 kg/m2), or overweight (BMI ≥27 kg/m2 to

GlobeNewsWire • Jun 11, 2026

Novo Nordisk A/S: IT Security incident at Novo Nordisk

Bagsværd, Denmark, 11 June 2026 – Novo Nordisk A/S has identified an IT security incident involving unauthorised access to a limited number of internal IT systems. Upon learning of the incident, we launched an investigation with the assistance of external cybersecurity experts, and we are in contact with the relevant authorities.

GlobeNewsWire • Jun 11, 2026

Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $43.93, denoting a +2.62% move from the preceding trading day.

Zacks Investment Research • Jun 11, 2026